Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and HaemostasisBusiness Wire • 04/06/23
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)Business Wire • 04/03/23
Down -19.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Rallybio Corporation (RLYB)Zacks Investment Research • 03/10/23
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune ThrombocytopeniaBusiness Wire • 03/06/23
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio's Inhibitor of Complement Component 5 (C5) and EyePoint's Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic AtrophyBusiness Wire • 02/27/23
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial OfficerBusiness Wire • 01/31/23
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023Business Wire • 01/05/23
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAITBusiness Wire • 12/15/22
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare DiseasesBusiness Wire • 12/01/22
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5Business Wire • 11/07/22
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune ThrombocytopeniaBusiness Wire • 09/28/22
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from SanofiBusiness Wire • 05/10/22